Figure 3.
![Comparison of rwOS after applying IPTW between patients with high-risk [presence of del(17p), del(11q), or unmutated IGHV] and non–high-risk CLL/SLL.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/15/10.1182_bloodadvances.2024015417/1/blooda_adv-2024-015417-gr3.jpeg?Expires=1756617046&Signature=ptJGTQZVTB340w4h~NU5~Yn719Aw3MbNyT3emGLp8oYudZhs7h1nx8LgFWBX66bkcmj7kIUT1W0XHIMQGtMSGi0B79D61SdWQkqGg2S6mi8iN0KStih8EIgKklZixJbIdF73FRna-OH-GDZdrCvHcyb5hVGJZnE8wSqNcH3YQ3luUGDQyrRKfp10yTBh0WFvpxd~-9G0h1nWikF0EkLmgjs6Ifv3YpknfN7vBa8pz-F70obrXdYkG25gq1lRIXF7mdFBz~FxnIhl00DJfcoZ6-sH8GXuBZ~hBqzMb1a0pKjgcJhuhX6TWwRKHZrYGfwFwhSggbLQ0PEuqDs2EzjCOw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Comparison of rwOS after applying IPTW between patients with high-risk [presence of del(17p), del(11q), or unmutated IGHV] and non–high-risk CLL/SLL.
Comparison of rwOS after applying IPTW between patients with high-risk [presence of del(17p), del(11q), or unmutated IGHV] and non–high-risk CLL/SLL.
